Tonix Pharmaceuticals (TNXP) Stifel 2025 Healthcare Conference summary

Financial and operational highlights

• Ended September with $190 million in cash, no debt, and a simple cap table; cash runway extends into Q1 2027, fully funding the product launch.

• Commercial launch of newly approved fibromyalgia treatment Tonmya set for before end of November, with experienced sales team and omnichannel prescriber engagement.

• Tonmya added to existing wholesaler and specialty pharmacy contracts; robust patient access and support services planned at launch.

• 25,000 healthcare providers write 70% of fibromyalgia prescriptions; 90 sales reps to target 70% of these prescribers.

• Recent acquisition of two acute headache products provided commercial foundation for Tonmya launch.

Product and market insights

• Tonmya is the first new fibromyalgia drug approved in over 15 years, with unique sublingual cyclobenzaprine formulation and patent exclusivity until 2034.

• Addresses significant unmet need: 10 million Americans affected, only 3 million diagnosed and treated; high dissatisfaction with current therapies and high off-label opioid use.

• Tonmya’s efficacy demonstrated by higher responder rates in clinical trials and favorable tolerability profile, with minimal withdrawal due to side effects.

• Commercial strategy includes proportional pricing for different patient groups and early prescriber outreach.

Pipeline and R&D updates

• Multiple pipeline programs advancing: TNX-102 SL for acute stress disorder (enrolling), major depressive disorder (study starts next summer), and prior PTSD studies provided strong mechanistic rationale.

• Anti-CD40 ligand antibody completed phase 1, phase 2 kidney transplant study to start in first half of next year in partnership with Mass General Hospital.

• TNX-4800, a long-acting antibody for Lyme disease, licensed from University of Massachusetts, phase 2 ready, offers immediate and season-long protection.

• Intranasal oxytocin/magnesium for Prader-Willi syndrome to enter pivotal study in second half of next year, supported by compelling animal data.